Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
OmniAb (OABI)
NASDAQ:OABI
Holding OABI?
Track your performance easily
OABI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.56 - $6.72
Previous Close$3.9
Volume309.82K
Average Volume (3M)414.66K
Market Cap
$464.69M
Enterprise Value$429.15M
Total Cash (Recent Filing)$59.38M
Total Debt (Recent Filing)$23.84M
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Mar 27, 2025EPS Estimate
-$0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding121,012,583
10 Day Avg. Volume589,467
30 Day Avg. Volume414,661
Standard Deviation0.15
R-Squared0.00089
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)1.62
Price to Sales (P/S)22.77
Price to Cash Flow (P/CF)-17.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue21.03
Enterprise Value/Gross Profit12.56
Enterprise Value/Ebitda-7.60
Forecast
1Y Price Target
$9.71Price Target Upside152.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
OmniAb News
PremiumCompany Announcements
OmniAb Reports Third Quarter 2024 Financial Results
PremiumCompany Announcements
OmniAb Board Reshuffles Following Tamaroff’s Departure
PremiumStock Analysis & Ideas
Insiders Load Up on These 2 Stocks — Here’s Why You Should FollowBulls Say, Bears Say
Bulls Say
Business GrowthOABI added an impressive 19 net programs, already more than double the 8 net adds in the first half of the year, demonstrating strong growth and market leadership in the antibody discovery space.
Financial PerformanceOABI's current partner pipeline from preclinical to registration comes with $550M+ in potential milestones, supporting management's belief it has adequate capital to reach cash flow profitability.
Partnerships And CollaborationsOmniAb entered into three new platform license agreements with 92Bio, Memorial Sloan Kettering Cancer Center, and Queen Mary University of London, showcasing its commitment to building a diversified portfolio backed by differentiated technologies.
Bears Say
Market ChallengesManagement noted continued macro challenges from large pharma pipeline prioritization and bifurcated funding of small biotechs.
Revenue PerformanceThe company reported revenue of $4.2 million compared to an estimate of $10.9 million.
Revenue ShortfallQ3 revenues of $4M missed consensus largely due to a delayed milestone payment and a drop in ion channel service revenues.
---
Ownership Overview
31.95% Insiders
18.95% Mutual Funds
32.83% Other Institutional Investors
7.13% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OABI FAQ
What was OmniAb’s price range in the past 12 months?
OmniAb lowest stock price was $3.56 and its highest was $6.71 in the past 12 months.
What is OmniAb’s market cap?
Currently, no data Available
When is OmniAb’s upcoming earnings report date?
OmniAb’s upcoming earnings report date is Mar 27, 2025 which is in 125 days.
How were OmniAb’s earnings last quarter?
OmniAb released its earnings results on Nov 12, 2024. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.138 by -$0.022.
Is OmniAb overvalued?
According to Wall Street analysts OmniAb’s price is currently Undervalued.
Does OmniAb pay dividends?
OmniAb does not currently pay dividends.
What is OmniAb’s EPS estimate?
OmniAb’s EPS estimate is -$0.1.
How many shares outstanding does OmniAb have?
OmniAb has 121,012,580 shares outstanding.
What happened to OmniAb’s price movement after its last earnings report?
OmniAb reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.138. Following the earnings report the stock price went down -9.354%.
Which hedge fund is a major shareholder of OmniAb?
Among the largest hedge funds holding OmniAb’s share is First Sabrepoint Capital Management Lp. It holds OmniAb’s shares valued at 7M.
---
OmniAb Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.71 (152.21% Upside)
$9.71 (152.21% Upside)
Blogger Sentiment
Bullish
OABI Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 197.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▲ 10.9%
Last 30 Days ▲ 10.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.71%
12-Months-Change
Fundamentals
Return on Equity
-20.45%
Trailing 12-Months
Asset Growth
-15.36%
Trailing 12-Months
Company Description
OmniAb
Avista Public Acquisition Corp II is a blank check company.
---
OABI Company Deck
---
OABI Earnings Call
Q3 2024
0:00 / 0:00
---
OABI Stock 12 Month Forecast
Average Price Target
$9.71
▲(152.21% Upside)
Technical Analysis
Best Analysts Covering OABI
1 Year
1 Year Success Rate
4/8 ratings generated profit
1 Year Average Return
+11.49%
reiterated a buy rating 10 days ago
Copying Puneet Souda's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +11.49% per trade.
---